Caladrius Biosciences Inc. (CLBS) is a Managed Health Care company listed on NASDAQ. There were no new wire items for CLBS in the last 30 days. The most recent was published Jan 17, 2023.
Latest news
25 items- INSIDERSEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Ruoslahti Erkki was granted 20,000 shares4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Klosk Steven M was granted 20,000 shares, increasing direct ownership by 198% to 30,090 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Henson Heidi was granted 20,000 shares4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Flowers Cynthia Louise was granted 20,000 shares, increasing direct ownership by 206% to 29,721 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Brown Gregory B was granted 20,000 shares, increasing direct ownership by 201% to 29,934 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Azab Mohammad was granted 20,000 shares, increasing direct ownership by 104% to 39,200 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Slack David W. was granted 24,000 shares and covered exercise/tax liability with 3,358 shares4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Mazzo David J was granted 60,000 shares and covered exercise/tax liability with 11,315 shares, increasing direct ownership by 99% to 97,970 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Buck Kristen K was granted 18,000 shares and covered exercise/tax liability with 2,659 shares, increasing direct ownership by 75% to 35,823 units4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- SECSEC Form 10-Q filed by Caladrius Biosciences Inc.10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form S-8 filed by Caladrius Biosciences Inc.S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)8-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits (Amendment)8-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form 424B5 filed by Caladrius Biosciences Inc.424B5 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- INSIDERSEC Form 3 filed by new insider Slack David W.3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 3: New insider Ruoslahti Erkki claimed ownership of 1,171,144 shares3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 3 filed by new insider Henson Heidi3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 4: Azab Mohammad was granted 19,200 shares4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERSEC Form 3 filed by new insider Azab Mohammad3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- SECCaladrius Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CALADRIUS BIOSCIENCES, INC. (0000320017) (Filer)
CLBS FAQ
6 questionsWhat does Caladrius Biosciences Inc. do?
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for...What is the latest news on CLBS?
Quantisnow has not tracked any new filings, ratings or press releases for CLBS in the last 30 days. The most recent wire item was published on January 17, 2023.Where does CLBS stock trade?
Caladrius Biosciences Inc. (CLBS) is listed on NASDAQ.What sector and industry is CLBS in?
Caladrius Biosciences Inc. operates in the Health Care sector, Managed Health Care industry.What companies are similar to CLBS?
Notable peers in the same industry include BRTX (BioRestorative Therapies Inc.), CERN (Cerner Corporation), CHNG (Change Healthcare Inc.), MTBC (CareCloud Inc.), CSLT (Castlight Health Inc.). Compare CLBS side-by-side with any of them on Quantisnow.How can I track CLBS on Quantisnow?
Quantisnow aggregates Caladrius Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLBS to receive live email and push alerts on every new disclosure.